These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 19627235)
1. Persistent immune responses induced by a human immunodeficiency virus DNA vaccine delivered in association with electroporation in the skin of nonhuman primates. Martinon F; Kaldma K; Sikut R; Culina S; Romain G; Tuomela M; Adojaan M; Männik A; Toots U; Kivisild T; Morin J; Brochard P; Delache B; Tripiciano A; Ensoli F; Stanescu I; Le Grand R; Ustav M Hum Gene Ther; 2009 Nov; 20(11):1291-307. PubMed ID: 19627235 [TBL] [Abstract][Full Text] [Related]
3. Persistent antibody and T cell responses induced by HIV-1 DNA vaccine delivered by electroporation. Cristillo AD; Weiss D; Hudacik L; Restrepo S; Galmin L; Suschak J; Draghia-Akli R; Markham P; Pal R Biochem Biophys Res Commun; 2008 Feb; 366(1):29-35. PubMed ID: 18036339 [TBL] [Abstract][Full Text] [Related]
4. mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients. Van Gulck E; Vlieghe E; Vekemans M; Van Tendeloo VF; Van De Velde A; Smits E; Anguille S; Cools N; Goossens H; Mertens L; De Haes W; Wong J; Florence E; Vanham G; Berneman ZN AIDS; 2012 Feb; 26(4):F1-12. PubMed ID: 22156965 [TBL] [Abstract][Full Text] [Related]
5. Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques. Luckay A; Sidhu MK; Kjeken R; Megati S; Chong SY; Roopchand V; Garcia-Hand D; Abdullah R; Braun R; Montefiori DC; Rosati M; Felber BK; Pavlakis GN; Mathiesen I; Israel ZR; Eldridge JH; Egan MA J Virol; 2007 May; 81(10):5257-69. PubMed ID: 17329330 [TBL] [Abstract][Full Text] [Related]
6. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma. Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252 [TBL] [Abstract][Full Text] [Related]
7. The Safety and Immunogenicity of GTU Haidari G; Day S; Wood M; Ridgers H; Cope AV; Fleck S; Yan C; Reijonen K; Hannaman D; Spentzou A; Hayes P; Vogt A; Combadiere B; Cook A; McCormack S; Shattock RJ Front Immunol; 2019; 10():2911. PubMed ID: 31921170 [TBL] [Abstract][Full Text] [Related]
8. Intradermal/subcutaneous immunization by electroporation improves plasmid vaccine delivery and potency in pigs and rhesus macaques. Hirao LA; Wu L; Khan AS; Satishchandran A; Draghia-Akli R; Weiner DB Vaccine; 2008 Jan; 26(3):440-8. PubMed ID: 18082294 [TBL] [Abstract][Full Text] [Related]
9. Induction of human immunodeficiency virus type-1-specific immunity with a novel gene transport unit (GTU)-MultiHIV DNA vaccine. Blazevic V; Männik A; Malm M; Sikut R; Valtavaara M; Toots U; Ustav M; Krohn K AIDS Res Hum Retroviruses; 2006 Jul; 22(7):667-77. PubMed ID: 16831091 [TBL] [Abstract][Full Text] [Related]
11. HIV-1 DNA vaccine efficacy is enhanced by coadministration with plasmid encoding IFN-alpha. Jiang W; Ren L; Jin N J Virol Methods; 2007 Dec; 146(1-2):266-73. PubMed ID: 17868910 [TBL] [Abstract][Full Text] [Related]
12. Potent specific immune responses induced by prime-boost-boost strategies based on DNA, adenovirus, and Sendai virus vectors expressing gag gene of Chinese HIV-1 subtype B. Yu S; Feng X; Shu T; Matano T; Hasegawa M; Wang X; Ma H; Li H; Li Z; Zeng Y Vaccine; 2008 Nov; 26(48):6124-31. PubMed ID: 18812199 [TBL] [Abstract][Full Text] [Related]
13. An HIV-based lentiviral vector as HIV vaccine candidate: Immunogenic characterization. Lemiale F; Asefa B; Ye D; Chen C; Korokhov N; Humeau L Vaccine; 2010 Feb; 28(8):1952-61. PubMed ID: 20188251 [TBL] [Abstract][Full Text] [Related]
14. Excellent safety and tolerability of the human immunodeficiency virus type 1 pGA2/JS2 plasmid DNA priming vector vaccine in HIV type 1 uninfected adults. Mulligan MJ; Russell ND; Celum C; Kahn J; Noonan E; Montefiori DC; Ferrari G; Weinhold KJ; Smith JM; Amara RR; Robinson HL; AIDS Res Hum Retroviruses; 2006 Jul; 22(7):678-83. PubMed ID: 16831092 [TBL] [Abstract][Full Text] [Related]
15. The site of administration influences both the type and the magnitude of the immune response induced by DNA vaccine electroporation. Vandermeulen G; Vanvarenberg K; De Beuckelaer A; De Koker S; Lambricht L; Uyttenhove C; Reschner A; Vanderplasschen A; Grooten J; Préat V Vaccine; 2015 Jun; 33(28):3179-85. PubMed ID: 25980430 [TBL] [Abstract][Full Text] [Related]
16. [Novel vaccines against M. tuberculosis]. Okada M Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920 [TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults. Gorse GJ; Baden LR; Wecker M; Newman MJ; Ferrari G; Weinhold KJ; Livingston BD; Villafana TL; Li H; Noonan E; Russell ND; Vaccine; 2008 Jan; 26(2):215-23. PubMed ID: 18055072 [TBL] [Abstract][Full Text] [Related]
19. Electroporation-mediated intradermal delivery of DNA vaccines in nonhuman primates. Adam L; Le Grand R; Martinon F Methods Mol Biol; 2014; 1121():309-13. PubMed ID: 24510834 [TBL] [Abstract][Full Text] [Related]
20. Immunogenicity, safety, biodistribution and persistence of ADVAX, a prophylactic DNA vaccine for HIV-1, delivered by in vivo electroporation. Dolter KE; Evans CF; Ellefsen B; Song J; Boente-Carrera M; Vittorino R; Rosenberg TJ; Hannaman D; Vasan S Vaccine; 2011 Jan; 29(4):795-803. PubMed ID: 21094270 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]